In 1894, Johns Hopkins surgeon William Stewart Halsted published the results of his “complete operation” for breast cancer — an en-bloc amputation of the breast, both pectoral muscles, and the axillary lymph nodes — and reported that it had cut local recurrence from the 51–82% rates of his European contemporaries to a fraction of that; the gap between that local-control victory and the survival it never delivered is the entire case. The radical mastectomy controlled the wound bed and was mistaken, for three-quarters of a century, for a control of the disease. It was performed on the order of nine in ten American women with breast cancer well into the 1970s, left them with a hollowed chest wall, a frozen shoulder, and near-ubiquitous arm lymphedema, and — as randomized trials would eventually show — bought not one additional day of survival over far lesser surgery.
The operation did not fail because it was crude. It was, by the standards of 1894, a genuine advance: Halsted’s en-bloc dissection and his obsession with surgical technique made him one of the founders of modern American surgery, and the early survival figures — a five-year survival roughly double that of untreated women — were real. The error was theoretical. Halsted built the operation on an anatomical hypothesis: that breast cancer spread in an orderly, centrifugal, contiguous fashion outward from the breast through the lymphatics, so that cutting wider and deeper must, by geometry, cut ahead of the disease. If the theory were true, more radical surgery would mean more cures. The theory was false.
Cancer that had spread had usually spread through the bloodstream before the surgeon ever arrived, and cancer that had not spread was cured by far less. The radical mastectomy’s mutilating margins therefore changed the scar without changing the outcome. Critics — Geoffrey Keynes in England, George “Barney” Crile Jr. at the Cleveland Clinic — argued this from the 1930s and 1950s and were dismissed by a surgical establishment that treated the Halsted operation as settled doctrine.
The reckoning came from a randomized trial run by a surgeon who had once performed the operation himself. Bernard Fisher’s NSABP Protocol B-04, begun in 1971, randomized 1,665 women among radical mastectomy and two lesser procedures; B-06, begun in 1976, added lumpectomy. At every follow-up out to 25 years, survival was statistically identical. The Halsted hypothesis of contiguous spread was replaced by the systemic-disease model — that breast cancer is, at diagnosis, often already a whole-body problem the scalpel cannot outrun. The radical mastectomy was not banned; it was abandoned, retired by evidence as the textbook case of a mutilating operation sustained for 75 years by an elegant theory that happened to be wrong.
For roughly the first three-quarters of the twentieth century, tonsillectomy was the most frequently performed operation in the United States — a near-compulsory rite of childhood scheduled on the order of a million-plus times a year for sore throats, “mouth breathing,” poor appetite, and the vague proposition that a child would simply be healthier without tonsils; the gap between that universal promise and the evidence is the entire case, because the operation was never shown to deliver the broad benefits claimed, killed a measurable number of the children it was sold to protect, and for a period in the 1940s demonstrably raised the risk of paralytic polio. At its 1959 peak roughly 1.4 million tonsillectomies were performed annually in the U.S., the overwhelming majority on children, and by mid-century an estimated 30 percent of American children had lost their tonsils — many to surgeons who, examined honestly, could not say why.
The procedure rode the “focal infection” theory: the early-twentieth-century belief that lurking pockets of chronic infection in the tonsils seeded disease throughout the body and were best excised pre-emptively. On that theory the indication became, in practice, the mere possession of tonsils. The surrogate that justified the knife was not a measured health outcome but a clinical impression — the tonsils “looked enlarged” — and impressions, it turned out, were nearly random. In 1934 the American Child Health Association sent 1,000 New York schoolchildren through successive examinations and found 61 percent had already been tonsillectomized; of the remaining 39 percent, physicians recommended surgery for all but 65, then for nearly half of those who had just been cleared, and again for nearly half of that residue — a recursive demonstration that the indication lived in the examiner, not the child.
The disconfirming evidence accumulated for forty years before the practice yielded. James Alison Glover’s 1938 study showed English tonsillectomy rates varying by an order of magnitude between districts with no relation to disease — the founding observation of “unwarranted variation,” still called the Glover phenomenon. From 1942 onward, epidemiologists documented that children tonsillectomized shortly before exposure to poliovirus suffered the deadly bulbar form at multiples of the background rate. And in 1984 the first rigorous randomized trial, by Jack Paradise in the New England Journal of Medicine, found a real but narrow benefit only for the most severely and frequently infected children — a tiny slice of those who had been operated on for decades. The operation was not banned. It was restricted, its indications tightened, its volume cut by more than half, retired from routine use by evidence that arrived long after the harm.
On October 30, 1967, in Zurich, the neurosurgeon M. Gazi Yaşargil sutured a scalp artery to a cortical branch of the middle cerebral artery under the operating microscope, rerouting blood around a blocked vessel to feed a starving brain; the operation was elegant, technically dazzling, and — for the prevention of stroke in patients with carotid and middle-cerebral disease — almost entirely unproven, and that gap between surgical beauty and clinical benefit is the entire case. For nearly two decades the extracranial-intracranial (EC-IC) arterial bypass spread on the strength of its own plausibility and on case series reporting open grafts, until a single randomized trial showed it prevented nothing it claimed to prevent.
The operation was never a fraud and never a mass killer in the lobotomy sense. It killed and disabled quietly, at the margins: a procedure with a roughly 12 percent thirty-day rate of stroke or death imposed up front on patients who, the trial would show, were no better protected afterward. The surrogate that sustained it was graft patency — the bypass stayed open in about 96 percent of cases, a number surgeons and angiograms could see and celebrate. A patent vessel looked like a prevented stroke. It was not the same thing, and conflating the two is the mechanism that kept the operation alive.
The reckoning arrived not from a regulator or a court but from an eight-year, NIH-funded randomized controlled trial led by the Canadian neurologist Henry J. M. Barnett of London, Ontario. Published in the New England Journal of Medicine on November 7, 1985, the International EC/IC Bypass Study randomized 1,377 patients at 71 centers in 14 countries and found that surgery added to best medical care did not reduce fatal or nonfatal stroke; two subgroups — patients with severe middle-cerebral stenosis and those with persisting symptoms after carotid occlusion — actually fared worse with the operation. Within a few years the procedure collapsed from a flourishing subspecialty to a narrow, rarely-indicated salvage technique. It was not banned. It was disconfirmed, and it became one of medicine’s foundational lessons in why a trial must precede an operation, not follow it.